Comparative Effectiveness of Oral Anticoagulants

Boehringer Ingelheim

Status: Completed

Conditions: Atrial Fibrillation

Study type: Observational

Funder types: Industry

Identifiers

NCT01847547

1160.157

Details and patient eligibility

About

This cohort study plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in patients with non-valvular atrial fibrillation at risk for stroke.

Enrollment: 5,982 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A recorded diagnosis of atrial fibrillation (AF).
• Initiation of anticoagulant medication (dabigatran or warfarin).
• At least 18 years of age on the date of anticoagulant initiation CHA2DS2-VASc-Score >=1

Exclusion criteria

• Patients with missing or ambiguous age or sex information
• Patients with documented evidence of valvular disease
• Patients with less than 12 months enrolment in the UnitedHealth Research Database preceding the date of anticoagulant initiation
• Patients with prior use of any oral anticoagulant

Trial design

5,982 participants in 2 patient groups

Dabigatran

Warfarin